Asim Ahmed Elnour*, Noura Al Hajri, Israa Yousif El Khidir, Abdulla Al Amoodi, Sahar Asim Ahmed and Adel Sadeq Pages 1 - 34 ( 34 )
Background: We thought to delve deeper seven meta-analyses of major clinical trials focusing on GlucagonLike Peptide-One Receptor Agonist (GLP-1 RA) cardio-protective effect.
Aim: We explored the role of GLP-1 RA in cardiovascular risk protection as primary outcome in subjects with type 2 diabetes mellitus.
Methodology: The current review has explored and critically appraised seven meta-analyses of placebo-controlled randomized clinical trials involving GLP-1 RA used in diabetes that have exhibited major cardiovascular events as primary outcome.
Results: The overall evidence for the cardio-protective effect of GLP-1 RA in diabetes was very clear in subjects with cardiovascular risk of varying degrees. Most of the current reviewed meta-analyses have not shown cardio-protection with GLP-1 RA in subjects with diabetes exhibiting high cardiovascular risk or medical history of cardiovascular diseases. Patient variability in addition to potency parameters will be the keys to successful member of the class. There will be avenues for selection of a candidate based on the suitability to patient preferences and characteristics.
Conclusion: The RCT-s for GLP-1 RA should characterize cardiovascular risk in subjects with diabetes such that disparities between established cardiovascular risk (high, moderate and low), or medical history of cardiovascular disease been accounted for in subgroup analysis.
cardiovascular diseases (CVD), glucagon like peptide 1 receptor agonist (GLP-1 RA), major adverse cardiovascular events (MACE), meta-analysis, and type 2 diabetes mellitus (T2DM)
College of Pharmacy, Gulf Medical University, Ajman, Department of Epidemiology and Population Health, Khalifa University, Abu Dhabi, Omdurman Islamic University, Omdurman, Al Ain hospital, Health Services Abu Dhabi, SEHA, Dental Clinic, Dubai, College of Pharmacy, Al Ain University, Al Ain